April 8, 2016—The Health Resources and Services Administration has taken another step toward amending the 340B Pharmaceutical Pricing Agreement to include drug manufacturer program integrity provisions in the Affordable Care Act. … [Read more...]
Price of Insulin More Than Doubled Since 2002
Study adds more fuel to controversy over rising drug pricesApril 7, 2016—Drug manufacturers more than doubled the price of insulin – which people with Type 1 diabetes need to stay alive – between 2002 and 2013, according to new research published in JAMA. … [Read more...]
CMS Gives Drugmakers Extension to Report 5i AMP Per Final Rule
July 1 is the new deadlineApril 6, 2016—The Centers for Medicare & Medicaid Services is giving drug manufacturers a three-month extension to begin calculating and reporting, in accordance with new federal regulations, the average manufacturer price for "5i" inhalation, infusion, instilled, implanted or injectable drugs that are not generally dispensed through retail community pharmacies. … [Read more...]
Drugmakers Took Hefty Price Increases Since 2011
Charges for top 10 drugs more than doubled in some casesApril 5, 2016—Prices for four of the nation's 10 most widely used prescription drugs more than doubled since 2011 and price hikes for the other six ranged from 96 percent to 54 percent, a Reuters wire service analysis of proprietary data has found. … [Read more...]
Lawmakers Want NIH to Rein in Cancer Drug’s Steep Cost
March 31, 2016—Twelve Members of Congress are urging the National Institutes of Health to respond favorably to a petition to use its statutory authority to lower the price of an expensive prostate cancer drug developed with taxpayer support. … [Read more...]
Physicians Group Calls for Action on Rising Drug Prices
Internists back tougher regulation of drug industryMarch 29, 2016—The nation's second-largest physician association is offering policymakers a multi-point plan to slow the rising cost of prescription drugs. … [Read more...]
Senator Skewers Turing Pharma Exec About Disputing 340B Claims
(Reprinted from the Drug Discount Monitor) The chairwoman of the Senate Special Committee on Aging excoriated a Turing Pharmaceuticals executive during a hearing today for instructing a subordinate to dispute 340B claims in order to boost company profits. The committee was holding its second hearing about Turing's toxoplasmosis drug Daraprim and other decades-old off-patent … [Read more...]